- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CCNE will focus on the application of PRINTTM nanoparticles and nanodevices for cancer therapy and imaging
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded the University of North Carolina-Chapel Hill one of seven centers of cancer nanotechnology research. These centers are an integral part of a $144.3 million, five-year initiative to develop and apply nanotechnology for the detection, diagnosis, and treatment of cancer. The Carolina Center of Cancer Nanotechnology Excellence (CCNE) will focus on the application of PRINTTM nanoparticles and nanodevices for cancer therapy and imaging. The CCNE will be headed by principal investigator Professor Rudolph Juliano and co-principal investigator Professor Joseph DeSimone.
PRINTTM particle technology results in unprecedented control over shape, size, and composition of material when manufacturing nanoparticles, resulting in drug delivery systems previously unattainable. The nanodevice technology includes the development of microfluidic chips from an innovative fluoropolymer technology. These chips have a unique combination of high performance features around precision molding, chemical resistance, gas permeability, and more.
"We are thrilled at the endorsement of these technologies by the NCI as a promising new era in cancer research. We believe both technologies have the potential to radically change human health care." says Professor DeSimone, National Academy of Engineering member and co-founder of Liquidia Technologies. Liquidia is a licensee of PRINTTM particles and microfluidic technologies from the university.
The new Carolina Center of Cancer Nanotechnology Excellence will be closely associated with UNC facilities including the Lineberger Comprehensive Cancer Center, Mouse Model of Human Cancer Consortium, the Biomedical Research Imaging Center, the Institute for Advanced Materials, Nanoscience and Technology, and the College of Arts and Sciences. The newly formed Center will also partner with not-for-profit organizations and private sector firms, with the specific intent of advancing the technologies being developed.
"NCI has supported the application of nanotechnology to cancer through a variety of programs and interactions with the scientific community for more than seven years, and we're very gratified that our activities are helping to advance a pipeline of new product opportunities," noted NCI Deputy Director Anna Barker, Ph.D. in the NCI press release. "Central to this initiative will be multidisciplinary partnerships involving physicists, biologists, clinicians, engineers, and other experts that can translate knowledge on cancer and nanotechnology into clinically useful products."
For more information about the NCI Alliance on Nanotechnology in Cancer, please visit nano.cancer.gov.
About Liquidia Technologies:
Located in Research Triangle Park, North Carolina, Liquidia Technologies develops and markets innovative fluoropolymer materials for high-value industrial applications in the electronics, life science, and chemical industries. Liquidia Technologies offers solutions in microfluidics and imprint lithography applications due to the beneficial qualities of its innovative material platform including solvent resistance, low surface energy, and elastomeric properties. Liquidia Technologies also brings precision, uniformity, and mass production techniques associated with the engineering of devices found in the microelectronics industry to the nanomedicine field for the fabrication and delivery of therapeutic, detection, and imaging agents for the diagnosis and treatment of human diseases.
For more information, please click here
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Nanopolymer-modified protein array can pinpoint hard-to-find cancer biomarker November 17th, 2016
Nanotechnology Treatment Found to Inhibit Mesothelioma Tumor Growth November 16th, 2016
Quantum obstacle course changes material from superconductor to insulator December 1st, 2016
Throwing new light on printed organic solar cells December 1st, 2016